How to Check Nephrocare Health IPO Allotment on KFinTech, NSE, BSE

Nephrocare Health’s ₹871.05 crore IPO, priced in the ₹438-₹460 band, ran from 10-12 December 2025 and saw strong demand across investor categories, especially on the final day. The basis of allotment is scheduled to be finalised on 15 December 2025, with a tentative listing date of 17 December 2025 on NSE and BSE.​

This blog will help you quickly check your Nephrocare Health IPO allotment status, review the subscription numbers, understand the latest GMP trend, and set realistic expectations for listing day.

Important Dates

• Allotment Date: December 15, 2025
• Initiation of Refunds: December 16, 2025
• Credit of Shares to Demat: December 16, 2025
• Listing Date: December 17, 2025

How to Check Nephrocare Health IPO Allotment Status?

Method 1: Check on BSE

• Open the BSE IPO allotment page: https://www.bseindia.com/investors/appli_check.aspx
• Choose Equity as the issue type.
• Select Nephrocare Health Services Ltd from the dropdown list.
• Enter your application number or PAN, and the captcha code.
• Click Search to see whether shares have been allotted to you.

Method 2: Check on NSE

• Go to the NSE IPO allotment status page: https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids
• Click on Equity & SME IPO bid details.
• Select Nephrocare Health Services Ltd from the issue name list.
• Enter your application number or PAN.
• Submit to view if you have received shares or not.

Method 3: Check on Registrar KFin Technologies

• Visit KFin Technologies’ IPO status page: https://ipostatus.kfintech.com
• Choose Nephrocare Health Services Ltd from the dropdown.​
• Select the search option: PAN, DP ID/Client ID, or Application Number.​
• Click Submit to see your detailed allotment status, including shares allotted and refund details.​

Nephrocare Health IPO Subscription Details

Source: chittorgarh.com

• The issue started quiet on Day 1 and Day 2, then saw a sharp jump on Day 3 with very heavy QIB and NII demand, taking the total subscription to 14.08 times.
• For retail investors, a 2.36 times subscription means roughly 1 in 2 or 1 in 3 applications getting full allotment, depending on the final basis.
• Heavy oversubscription in QIB and NII reduces the chance of large allocations for small investors and makes single-lot retail applications more like a lucky draw.

Also Read: What Nephrocare Health’s ₹871 Crore IPO Means for Investors

Nephrocare Health IPO GMP Update

Nephrocare Health’s grey market premium (GMP) started at ₹0 before the IPO opened, implying no listing gain, then turned positive and moved between mid-teens and mid-30s during the issue before reaching about ₹39 on allotment day, hinting at an 8-9% premium over the upper price band. The trend shows sentiment improving steadily across the IPO window as subscription built up, especially from institutional and high-net-worth investors.

Disclaimer: GMP is an unofficial, unregulated indicator, can be very volatile and should never be the sole basis for an investment decision.

What’s Next After Allotment?

If shares are allotted

• Your allotted shares will be visible on the BSE/NSE and KFin allotment status pages once the basis is finalised.​
• Shares should get credited to your demat account on or around 16 December 2025, before listing.​
• In case of partial allotment, only the blocked amount for unallotted shares will be released back to your bank or UPI, while funds equal to allotted shares remain debited.
• After demat credit, you can choose to hold for the long term or sell on or after listing, depending on your view of business quality, valuation, and listing price action.

If shares are not allotted

• Your application money will be refunded, or your UPI mandate will be unblocked, typically from 16 December 2025 onwards.​
• You will not receive any shares in your demat account for this IPO.
• You can still buy Nephrocare Health shares from the secondary market after listing if the price and your risk appetite match.
• Given the strong overall subscription, especially from institutions, non-allotment is common and mainly a function of oversubscription and the lottery process.

For detailed information, visit Nephrocare Health’s official IPO page at INDmoney.

Final Word

Nephrocare Health’s IPO combines a strong market position in dialysis, healthy growth, and improving margins with a clearly rich valuation, so listing gains may track sentiment more than pure fundamentals in the very short term. For small investors, the heavy QIB and NII demand and rising GMP support the possibility of a positive listing, but the high P/E and contract risks mean any position size should stay sensible and aligned with a multi-year view rather than a quick flip.

For more IPOs, check INDmoney’s IPO tracker here.

Disclaimer

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. The securities are quoted as an example and not as a recommendation. This is nowhere to be considered as advice, recommendation, or solicitation of an offer to buy or sell or subscribe for securities. INDStocks SIP / Mini Save is a SIP feature that enables Customer(s) to save a fixed amount on a daily basis to invest in Indian stocks. INDstocks Private Limited (formerly known as INDmoney Private Limited) 616, Level 6, Suncity Success Tower, Sector 65, Gurugram, 122005, SEBI Stock Broking Registration No: INZ000305337, Trading and Clearing Member of NSE (90267, M70042) and BSE, BSE StarMF (6779), SEBI Depository Participant Reg. No. IN-DP-690-2022, Depository Participant ID: CDSL 12095500, Research Analyst Registration No. INH000018948 BSE RA Enlistment No. 6428. Refer to https://indstocks.com/pricing?type=indian-stocks; https://www.indstocks.com/page/indian-stocks-sip-terms-and-condition for further details.